Effect of Resveratrol and Vitamin C on Insulin Resistance Among Postmenopausal Women

NCT ID: NCT03090997

Last Updated: 2021-12-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-15

Study Completion Date

2022-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hormonal and metabolic changes because of postmenopause increase body weight, central abdominal fat, alter lipid profile and insulin resistance, those factors increase the risk up to 60% to develop metabolic syndrome, diabetes and cardiovascular diseases. Because there is no efficient antioxidant therapy in postmenopausal women, this study proposes a therapy with resveratrol and vitamin C to increase the total antioxidant capacity; as well as to decrease insulin resistance and in consequence decreased the risk of diabetes, metabolic syndrome and cardiovascular disease

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently, there are not studies that demonstrate an efficient antioxidant therapy in postmenopausal women, to increase the total antioxidant capacity and to decrease insulin resistance and biochemical parameters of cardio-metabolic risk. Therefore, the aim of this study is to evaluate the effect of the co-administration of resveratrol and vitamin C on insulin resistance and antioxidant capacity by a double-blind randomized clinical trial. A population of 270 postmenopausal women will be studied, stratified into 3 groups:

Group 1: Three-month administration of vitamin C 500 mg daily + placebo Group 2: Three-month administration of resveratrol 500 mg daily + placebo Group 3: Three months administration of vitamin C 500 mg daily and resveratrol 500 mg daily as antioxidant therapy.

All participants will be monitored monthly for a period of 3 months: glucose, insulin, uric acid, Homeostatic Model Assessment (HOMA), total cholesterol (TC), triglycerides (TGC), High density lipoproteins-cholesterol (HDL- C), low density lipoproteins-cholesterol (LDL), blood pressure, body mass index (BMI). The antioxidant efficiency in erythrocytes by the quantification of antioxidant enzymes (superoxide dismutase, catalase, glutathione reductase and glutathione peroxidase), as well as total antioxidant capacity in plasma. In order to corroborate the oxidative damage, the product of the lipoperoxidation malondialdehyde and the carbonylation of proteins will be evaluated by spectrophotometric techniques before and three months after the intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postmenopausal Insulin Resistance

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

resveratrol, vitamin C, antioxidant therapy, antioxidant capacity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized Clinical Trial
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Participant, care provider, investigator and outcomes assesor will be masking using placebo for resveratrol and vitamin C, the three groups will receive the same intervention with the use of placebo. The placebo will be prepared for the Pharmacology Department and packing and label for exclusive use into the protocol study. Any participant, care provider or investigator will know if package content vitamin C, resveratrol or placebo.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

vitamin C (500 mg/day/orally) + placebo

Group Type PLACEBO_COMPARATOR

vitamin C (500 mg / day) + placebo

Intervention Type DIETARY_SUPPLEMENT

Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)

Group 2

resveratrol (500 mg/day/orally) + placebo

Group Type PLACEBO_COMPARATOR

resveratrol (500 mg / day) + placebo

Intervention Type DIETARY_SUPPLEMENT

Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)

Group 3

vitamin C (500 mg/day/orally) + resveratrol (500 mg/day/orally)

Group Type ACTIVE_COMPARATOR

vitamin C (500 mg / day) and resveratrol (500 mg / day)

Intervention Type DIETARY_SUPPLEMENT

Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vitamin C (500 mg / day) + placebo

Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)

Intervention Type DIETARY_SUPPLEMENT

resveratrol (500 mg / day) + placebo

Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)

Intervention Type DIETARY_SUPPLEMENT

vitamin C (500 mg / day) and resveratrol (500 mg / day)

Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women diagnosed with early postmenopause according to STRAW classification.
* Insulin resistance determinated by HOMA ≥ 2.5.
* Not use of metformin, bezafibrates and / or statins, three months before enter to the study
* No indication of hormone replacement therapy.
* Sign the informed consent.

Exclusion Criteria

* Women who present pathologies such as: Diabetes Mellitus, rheumatoid arthritis, lupus, neoplasms of any type, HIV, or kidney disease during the course of the study.
* Women who during the development of the protocol require hormone replacement therapy.
* Any type of surgical intervention during the following of the study.
* That the patient wishes to withdraw from the study.
* That the patient does not complete with 80% of adherence to the treatment
Minimum Eligible Age

50 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

ENRIQUE REYES-Munoz MD

Clinical Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Araceli Montoya-Estrada, PhD

Role: PRINCIPAL_INVESTIGATOR

Instituto Nacional de Perinatología Isidro Espinosa de los Reyes

Guillermo F Ortiz-Luna, MD

Role: STUDY_CHAIR

Instituto Nacional de Perinatología Isidro Espinosa de los Reyes

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Instituto Nacional de Perinatología Isidro Espinosa de los Reyes

Mexico City, , Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Mexico

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3210-10209-01-574-17

Identifier Type: -

Identifier Source: org_study_id